Episode Transcript
[00:00:09] Speaker A: In hospital halls under fluorescent bloom, they took my blood and listened to the room.
[00:00:20] Speaker B: Welcome to Base by Base, the papercast that brings genomics to you wherever you are. Thanks for listening, and don't forget to follow and rate us in your podcast. Appreciate. Imagine, just for a moment, that you or someone you love has just gone through, like, the most grueling cancer treatment imaginable.
[00:00:36] Speaker C: Oh, yeah.
Months of intense therapy.
[00:00:39] Speaker B: Exactly. Harsh side effects, this unrelenting emotional rollercoaster, and then finally, your doctor walks in and delivers the incredible news. Right. You are in complete remission.
[00:00:49] Speaker C: It's the exact moment you've been praying for.
[00:00:51] Speaker B: Right.
But deep down, there is this terrifying medical reality kind of lingering in the shadows. Like, what if a microscopic fraction of the disease is still hiding somewhere in your body, completely invisible to standard medical tests?
[00:01:05] Speaker C: I mean, it is the ultimate nightmare scenario for both patients and oncologists because visually, the cancer appears gone. The blood counts have recovered, but, you know, at a molecular level, it might
[00:01:16] Speaker B: just be biting its time, quietly preparing to return. Yeah, so in this deep dive, we're asking, how do doctors track an invisible enemy hiding inside your body?
And what actually happens when we swap out painful localized bone marrow biopsies for a simple, highly personalized blood test that basically reads the unique genetic baggage of the tumor itself?
[00:01:40] Speaker C: Well, today we celebrate the work of Yuksu Wan Wang, Lucas P. Gondek, Bert Vogelstein, Nicholas Papadopoulos and their colleagues at the Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center.
[00:01:53] Speaker B: A really incredible team.
[00:01:54] Speaker C: Absolutely. They have advanced our understanding of measurable residual disease by publishing the research article, a Plasma Based DNA Test for Quantification of Disease burden in Acute Myeloid Leukemia Patients Undergoing Bone Marrow Transplantation, in the journal PNAS on April 14, 2026.
[00:02:11] Speaker B: Okay, so to really grasp the mechanics of what this team accomplished, we have to look at the specific disease they are targeting, which is acute myeloid leukemia, or, you know, aml. It's an aggressive cancer of the blood and bone marrow.
[00:02:23] Speaker C: And.
[00:02:23] Speaker B: And the marrow is essentially your body's blood cell factory. So in aml, that factory just gets entirely overrun by these rapidly dividing dysfunctional cells.
[00:02:33] Speaker C: Yeah. And for many patients, really, the only true shot at a cure is an allogeneic hematopoietic cell transplant, which is, in simpler terms, a bone marrow transplant from a healthy donor.
[00:02:45] Speaker B: And that transplant process is. I mean, it's an incredibly intense biological undertaking. Right.
[00:02:50] Speaker C: It really is. Before receiving the new cells, the patient has to undergo what is called conditioning therapy. So this usually involves very severe chemotherapy or radiation designed to be myeloablative.
[00:03:00] Speaker B: Meaning it intentionally wipes out the patient's own diseased bone marrow.
[00:03:04] Speaker C: Exactly. It entirely suppresses their immune system so that their body will not reject the incoming donor cells.
[00:03:10] Speaker B: So let me make sure I've got this. You are basically burning the faulty factory to the ground so you can build a brand new one using a donor's blueprints.
[00:03:18] Speaker C: That is precisely it. And once the conditioning is complete, they infuse the healthy donor stem cells. And the goal here is twofold. First, obviously, you need to replace the patient's blood forming system.
[00:03:29] Speaker B: Right. They need new blood.
[00:03:30] Speaker C: But second, and just as crucially, you want to unleash the donor's healthy immune cells to sort of hunt down and destroy any remaining leukemia cells that somehow survived the chemotherapy.
[00:03:41] Speaker B: Wow.
[00:03:41] Speaker C: Yeah. In the medical field, we call this the graft versus leukemia effect.
[00:03:45] Speaker B: But to know if any of this intense therapy is actually working, doctors have to measure what is called mrd, or measurable residual disease.
And the traditional way we measure MRD Sounds pretty archaic.
[00:03:58] Speaker C: Oh, it really does.
[00:03:59] Speaker B: You undergo a bone marrow aspiration. Like a doctor literally inserts a needle directly into your hip bone to pull out a sample of the marrow. Then they send those cells to a lab where they use a technique called flow cytometry. Right, and from my understanding, they essentially shoot lasers at the cells to look for specific protein markers on their surface. Or maybe they run a standard genetic test looking for one or two well known cancer mutations.
[00:04:23] Speaker C: Yeah, that is exactly how it is done today. And honestly, it has significant flaws. I mean, beyond the obvious physical pain and the logistical nightmare of making a patient repeat a bone marrow biopsy, the tests simply are not sensitive enough.
[00:04:37] Speaker B: Because they're constrained by the physical limits of the sample size.
[00:04:41] Speaker C: Exactly.
Even utilizing these tests, about 30% of patients who are declared MRD negative, meaning the test found absolute zero evidence of cancer, still tragically go on to relapse after their transplant.
[00:04:55] Speaker B: So the cancer was undeniably there. The test just failed to find it.
[00:04:58] Speaker C: Exactly.
[00:04:58] Speaker B: Okay, let's unpack this for a second. Using a single bone marrow biopsy to declare the whole body cancer free is. Well, it's like trying to figure out if you have termites by only checking under one specific floorboard.
[00:05:10] Speaker C: That's a great way to put it.
[00:05:11] Speaker B: Right. And having to physically drill a hole in your floor every single time you want to check. You might pull up a completely clean piece of wood, but the colony could be thriving just a few feet away.
[00:05:22] Speaker C: That analogy perfectly illustrates the spatial limitation of biopsies. Because bone marrow is this vast network distributed throughout your entire skeletal system.
Pulling a tiny sample from one pelvic bone does not give you a comprehensive map of the disease landscape.
[00:05:39] Speaker B: Which is the exact clinical dilemma the Johns Hopkins team set out to solve.
[00:05:43] Speaker C: Yes, with an innovation they call the V96 assay.
[00:05:46] Speaker B: And the way this V96 assay flips the whole testing paradigm on its head is just fascinating to me. Can you break down the actual workflow? Like, if a patient walks into the clinic, how does this process physically unfold?
[00:05:57] Speaker C: Sure. So it begins right at the time of their initial diagnosis, before the major treatments even begin. The researchers take a sample of the patient's active leukemia cells and perform whole genome sequencing.
[00:06:09] Speaker B: Okay. So they read the entire genetic code of that specific person's cancer.
[00:06:12] Speaker C: Exactly. And from that massive data set, they identify up to 96 unique mutations that are present in the leukemia. Using those specific mutations, they design a completely customized primer panel. Oh, wow. So they are essentially building a bespoke, unique testing kit for that one single individual.
[00:06:30] Speaker B: You got it. They build a custom barcode scanner designed only to recognize that exact patient's tumor.
[00:06:37] Speaker C: But instead of drilling into the bone marrow repeatedly to use that scanner, they shift entirely to the blood.
[00:06:43] Speaker B: Yes. They take a standard, minimally invasive blood drop. They are specifically looking for cell free DNA, or CF DNA just floating in the blood plasma.
[00:06:53] Speaker C: I want to pause on that because the mechanics of cell free DNA are really important here. How does the cancer's DNA actually get out of the bone marrow and into the bloodstream in the first place?
[00:07:04] Speaker B: Well, it comes down to cell death. When cells, including cancer cells, by the way, naturally die through apoptosis or are killed off by therapies, they eventually degrade and burst open.
[00:07:13] Speaker C: Okay.
[00:07:14] Speaker B: And when they burst, their internal contents, including fragments of their DNA, sort of spill out into the surrounding tissue and eventually wash into the bloodstream. So by using their customized 96 target panel, the researchers can continuously monitor the blood plasma before and after the bone marrow transplant, just looking for those specific genetic fragments.
[00:07:35] Speaker C: Precisely.
[00:07:35] Speaker B: And the technology they use to actually read these tiny fragments of DNA is crucial. Right. Because finding rare mutations in the blood is notoriously difficult.
[00:07:45] Speaker C: Very difficult. Yeah. They use a technique called duplex sequencing, specifically a proprietary method called safer sex.
[00:07:52] Speaker B: Okay. Safer sex.
[00:07:53] Speaker C: Right. The problem with standard DNA sequencing is that the chemical process of complex copying and reading the DNA can actually introduce random errors. If you get a typo in your reading process, you might get a false Positive. Telling a patient they have cancer when they actually do not.
[00:08:07] Speaker B: Right. Which would be devastating. So why is duplex sequencing better?
[00:08:10] Speaker C: Well, to understand how it works, visualize the classic DNA double helix as a twisted ladder with two side rails. We call these the Watson strand and the Crick strand.
[00:08:20] Speaker B: Okay.
[00:08:20] Speaker C: Watson and Crick standard sequencing often just reads one side of the ladder.
So if an error occurs during the chemical amplification process, it looks exactly like a real mutation.
[00:08:31] Speaker B: Ah, I see. It's like comparing the original negative of a photograph to the printed picture. If there is a random scratch on the print, but you look back and see the negative is perfectly clear, you immediately know it is just a printing error, not a physical object in the original photo.
[00:08:47] Speaker C: That is a perfect way to look at it. By checking both the Watson and the crick strands of the DNA ladder, they immediately spot the errors.
[00:08:55] Speaker B: So if a mutation isn't perfectly mirrored on both rails of the ladder, the test just throws it out as a technical artifact.
[00:09:01] Speaker C: Exactly. That double verification physically eliminates nearly all false positives. But the sensitivity of the V96 assay isn't just about the sequencing technology. It is deeply tied to the biological strategy of which mutations they actually chose to track.
[00:09:18] Speaker B: Okay, what do you mean?
[00:09:19] Speaker C: Well, rather than focusing on the well known driver mutations that actually cause the leukemia. And they deliberately designed their panels to track up to 96 passenger mutations.
[00:09:28] Speaker B: Wait, here's where it gets really interesting, but also a bit confusing for me.
Why track passenger mutations? Aren't driver mutations the ones actually causing the cancer? Shouldn't we be watching the driver?
[00:09:41] Speaker C: Yeah, no, it seems totally counterintuitive. Driver mutations are the genetic errors that fundamentally break the cell's programming and, you know, drive the uncontrolled cancer growth. They are functionally critical.
[00:09:52] Speaker B: Right.
[00:09:53] Speaker C: However, there are typically only 12 driver mutations present in a patient's leukemia. Passenger mutations, on the other hand, are functionally irrelevant.
[00:10:02] Speaker B: Irrelevant?
[00:10:03] Speaker C: Yeah, they do not cause the cancer. They are simply random genetic typos that accumulated as the cell aged. They are just the cancer's baggage.
[00:10:11] Speaker B: So why is the useless baggage a better target than the critical engine of the cancer?
[00:10:15] Speaker C: It has to do with a principle called clonal evolution. Every single leukemia cell in a patient's body originally ascended from one single rogue founder cell.
[00:10:26] Speaker B: Okay.
[00:10:27] Speaker C: Before that founder cell ever turned cancerous, it had already lived a long life, accumulating its own random collection of passenger mutations, often 60 to 100 of them.
[00:10:35] Speaker B: Oh, I see where this is going.
[00:10:37] Speaker C: Right. When that cell finally acquired a driver mutation and began rapidly Multiplying, it copied all of its historical baggage into every single descendant cell.
So millions of leukemia cells all share this exact same homage. Highly unique barcode of passenger mutations.
[00:10:53] Speaker B: Wow, that makes perfect sense statistically. If you only look for one driver mutation, it is easy to miss. And some driver mutations are in regions of the genome that are naturally prone to reading errors.
But casting a wide net for 96 unique pieces of baggage makes the test exponentially more powerful. So they have this highly specific 96 target net.
What happens when they actually cast it?
[00:11:17] Speaker C: The results fundamentally challenge how we define remission. The researchers evaluated 30 patients who had achieved what is clinically defined as complete remission right before their bone marrow transplants.
[00:11:28] Speaker B: Okay, so they are supposedly cancer free.
[00:11:30] Speaker C: Supposedly. When doctors used the standard flow cytometry test on their bone marrow, it detected residual leukemia in only 20% of the patients. That is just six out of 30 people.
[00:11:41] Speaker B: But when they took plasma samples from those exact same 30 patients and ran the custom V96 assay, it detected residual disease in 100% of them.
[00:11:51] Speaker C: 100%.
[00:11:53] Speaker B: Every single patient still had leukemia DNA actively circulating in their blood.
[00:11:58] Speaker C: It forces a hard realization. Honestly, complete clinical remission is in many ways an illusion. The disease was actively present in all 30 patients, completely invisible to the conventional tools we rely on to make life and death quickly clinical decisions.
[00:12:11] Speaker B: So if the blood test caught the cancer in all 30 patients, when the bone marrow test completely failed, it begs the question, why is the blood actually a better hiding spot to look for cancer than the bone marrow itself?
[00:12:24] Speaker C: That's a great question.
[00:12:25] Speaker B: Because the traditional expert consensus has always been that the marrow is the ultimate source of truth for leukemia, right?
[00:12:31] Speaker C: Yeah. But the data from this study proves otherwise. When the team compared the matched samples side by side, the mutant allele frequency, which is essentially the concentration of cancer, cancer DNA relative to healthy DNA, was vastly higher in the blood plasma than in the bone marrow.
[00:12:46] Speaker B: Really? How much higher?
[00:12:47] Speaker C: On average, the concentration was 2.9% in the plasma, compared to a mere 0.42% in the marrow.
[00:12:55] Speaker B: I was trying to picture how that physically works. And it comes back to how cell free DNA behaves in the body. It doesn't just float around in your veins forever, does it?
[00:13:02] Speaker C: No, not at all. It is highly transient. Cell free DNA in the bloodstream has a half life of only about one hour. Wow.
[00:13:09] Speaker B: Just an hour.
[00:13:10] Speaker C: Yeah. Your liver and kidneys are constantly filtering it out and degrading it. So because it disappears so quickly, finding cancer DNA in the blood is not a historical record. Of a tumor cell that died three weeks ago.
[00:13:22] Speaker B: Right.
[00:13:22] Speaker C: It is a live, real time broadcast of what is happening inside the body right this very minute.
[00:13:28] Speaker B: And the math behind that live broadcast is just staggering. The researchers calculated that finding just one single mutant molecule in a standard 10 milliliter plasma sample means that a minimum of 3,000 leukemia cell actively dying and shedding their DNA into the circulatory system every single day.
[00:13:46] Speaker A: It's incredible.
[00:13:47] Speaker B: So even a tiny trace of DNA means there is a massive active war going on inside the patient. And because blood circulates everywhere, it act as a real time aggregator for the whole body. You aren't checking one bone, you are checking the exhaust system for the entire skeletal structure.
[00:14:04] Speaker C: Absolutely. And this brings us to the ultimate test of any new diagnostic tool.
Can it actually predict who is going to get sick again?
[00:14:11] Speaker B: Right, the predictive power.
[00:14:13] Speaker C: Keep in mind the timeline here. The researchers analyzed the levels of mutant DNA in the patient's plasma Just seven days prior to them receiving their bone marrow transplant.
[00:14:22] Speaker B: Okay.
[00:14:23] Speaker C: For the patients who eventually suffered a clinical relapse months or even years later, Their median mutant molecule count right before the transplant was 352 fold higher than those who remained in long term remission.
[00:14:35] Speaker B: 352 fold.
[00:14:36] Speaker C: Yeah. We are looking at a median of 36,305 Newton molecules versus just 103.
[00:14:41] Speaker B: A 352 fold difference is not a subtle warning sign. That is a blaring siren.
[00:14:46] Speaker C: Oh, complete.
[00:14:46] Speaker B: And that predictive power continued after the transplant too, didn't it? If a patient's mutant DNA levels started to rise again in the blood post transplant, that molecular spike predicted a clinical relapse, Meaning the moment a doctor could actually see the cancer returning in a hospital scan or blood cell count by an average of 123 days.
[00:15:06] Speaker C: 123 days of lead time. In the field of oncology, four months is an eternity.
[00:15:12] Speaker B: It really is.
[00:15:13] Speaker C: It is the crucial difference between reacting to an entrenched, physically robust disease and proactively attacking a microscopic molecular recurrence before it establishes a foothold.
[00:15:24] Speaker B: And just to close the loop on the biological strategy, the researchers actually ran a direct comparison. Right.
To see what would have happened if they had ignored the passenger mutations and only tracked the driver genes Using this same ultra sensitive sequencing technology.
[00:15:38] Speaker C: They did. And the comparison perfectly validated their hypothesis about clonal evolution. If they had relied solely on driver genes, they would have completely missed the presence of the disease in 52% of the patients prior to transplant. Over half of them and at two months post transplant, they would have missed it in 50% of the patient. Patients, the drivers are simply too scarce. And occasionally, a cancer will actually evolve to drop its original driver mutation while retaining its historical passenger baggage.
[00:16:07] Speaker B: So by tracking up to 96 passengers, you create this inescapable fingerprint.
[00:16:12] Speaker C: Exactly.
[00:16:13] Speaker B: So we have this highly sensitive tool. But reading the paper, the most captivating part for me was how this tool allowed the researchers to watch the human immune system actually do its job in real time.
[00:16:25] Speaker C: It is perhaps the most elegant physiological insight in the entire study. We spoke earlier about the graft versus leukemia effect. The donor's immune cells hunting the cancer. But there is a massive catch, right?
[00:16:36] Speaker B: The immunosuppression.
[00:16:37] Speaker C: Yes. After a transplant, doctors must give the patient intense immunosuppression drugs like cyclosporine. If they do not, the new foreign immune system will recognize the patient's entire body as an invader and attack their
[00:16:49] Speaker B: healthy tissues, which is a highly dangerous condition called graft versus host disease. It is a terrifying balancing act. You need the new immune system to wake up and fight the leukemia, but you have to keep it heavily sedated so it doesn't attack the patient's liver or skin.
[00:17:04] Speaker C: Yeah. And historically, deciding when it is safe to slowly taper off those immunosuppressant drugs has involved a lot of clinical guesswork.
But utilizing the V96 assay, researchers could continuously track the physical burden of the cancer.
They observed that in 20 out of 22 patients who had residual disease lingering after their transplant, the leukemia DNA levels only started to definitively plummet after the doctors discontinued the immunosuppression drugs.
[00:17:33] Speaker B: So if you are listening to this and wondering what this all means in practice, it's like doctors finally have a high definition, real time dial for immunosuppression.
[00:17:41] Speaker C: That's exactly what it is.
[00:17:42] Speaker B: Instead of blindly guessing when to take the brakes off the new immune system system, they can literally watch the cancer cells drop in the blood.
If they lower the drug dose and the cancer DNA immediately plummets, they have physical proof that the donor T cells have woken up and are actively clearing the battlefield.
[00:17:58] Speaker C: It replaces intuition with precise molecular data. And looking toward the future of clinical practice, the implications here represent a total paradigm shift. For sure, we are moving toward a reality where painful, localized bone marrow biopsies are largely replaced by frequent non invasive blood tests. If an oncologist sees a massively high mutation burden in the plasma seven days before transplant, they might dynamically alter the conditioning regimen. Perhaps opting for a much more intense myeloablative therapy.
[00:18:30] Speaker B: Or if they see the DNA levels rising after the transplant, they have that 123 day window to intervene.
[00:18:36] Speaker C: Precisely. They could administer targeted immunologic therapy or provide donor lymphocyte infusions, which essentially means giving the patient a booster shot of active immune cells from their original donor long before the patient ever feels sick.
[00:18:49] Speaker B: Wow.
[00:18:50] Speaker C: However, as with all cutting edge science, we must acknowledge the limitations.
[00:18:53] Speaker B: Right. 30 patients is a relatively small sample size to change global medical protocols.
[00:18:58] Speaker C: Absolutely. The statistical significance within this specific cohort is undeniably strong. But the medical community requires large, prospective, multi center clinical trials.
[00:19:08] Speaker B: We need more data.
[00:19:09] Speaker C: Yes, we need to validate exactly how a physician should alter treatment based on these precise DNA numbers. Knowing the cancer is returning four months early is a monumental breakthrough, but we still need to definitively prove which preemptive treatments will save the patient's life without causing undue toxicity, which is the necessary
[00:19:28] Speaker B: next step for the scientific method. Still, the underlying biology they have uncovered here is just remarkable. So to wrap up all these different mechanisms and clinical data points, how would you distill the core takeaway from this deep dive?
[00:19:40] Speaker C: The V96 assay clearly demonstrates that tracking a highly personalized panel of passenger mutations via cell free DNA in the blood is vastly more sensitive and informative than standard bone marrow biopsies. It provides a non invasive real time window into tumor dynamics, allowing oncologists to accurately predict relapse and physically visualize the immune response at work. And it really forces us to ask, what does this mean for the future of personalized medicine? Could tracking our cancer's unique genetic baggage in real time eventually allow us to turn a fatal, unexpected relapse into a highly manageable, precisely timed chronic condition?
[00:20:18] Speaker B: This episode was based on an Open Access article under the CCBY 4.0 license. You can find a direct link to the paper and the license in our episode Description Description if you enjoyed this, follow or subscribe in your podcast app and leave a five star rating. If you'd like to support our work, use the donation link in the description now. Stay with us for an original track created especially for this episode and inspired by the article you've just heard about. Thanks for listening and join us next time as we explore more science base by base.
[00:20:53] Speaker A: In hospital halls under fluorescent bloom they took my blood and listened to the room not in the marrow, too deep, too hard to find but in the plasma the echoes left behind 96 names a constellation of small scars Passenger whispers travin like stars, strand by strand. Truth precise and clean, showing what remission really means. Read the river, not the stone Count the sparks before they're grown if the shadow wants to rise, we'll see it coming in my bloodline's tide hold alive, let the signal fight 96 names in the light.
Two months out and the charts still glow A quiet burden where the eye says no.
Some fall only when the guards step back when the immune fire runs down the track I don't need a needle to the bone to know I need a window where the numbers show. Turn down the shield, let the graph defend and chase the last bad clone to the end.
Read the the river, not the stone Count the sparks before they're grown From a single drop, A clearer sign guiding every hard decision down the line hold the line, let the signal fight.
96 names in the line.
Sam.
